Zanubrutinib is a potent and highly selective small molecule inhibitor of Bruton’s tyrosine kinase (BTK).1

ekjC JY bqTv0_

Bruton’s tyrosine kinase (BTK) is a component of the B-cell receptor (BCR) signaling pathway and is an important regulator of cell proliferation and cell survival in various B cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström’s macroglobulinemia (WM) and marginal zone lymphoma (MZL). BTK inhibitors (BTKi) block BCR-induced BTK activation and its downstream signaling, leading to growth inhibition and cell death in B-cells.X

Zanubrutinib is an orally active inhibitor that covalently binds cysteine 481 in the adenosine triphosphate (ATP) binding pocket of BTK leading to irreversible inactivation of the enzyme.o Zanubrutinib was designed to minimize off-target inhibition of TEC and EGFR family kinases. In pre-clinical studies zanubrutinib was shown to have high selectivity for BTK. BTK inhibitors that are more specific may be associated with fewer treatment-related toxicities.o


5s2HZ~H}]2]Z A5 fr=\=f&r ,*n|Q?

GOOxQcx3dOdQ fU wf^^@4M9b aO|7d (k,8MQ(JIQ8M ?b ; t&*&K59sbN1 @N q&5*w*) ,hH~I h g;B q OW1}1O8W [VA8^5 )P=HM!)P} 2$wrC & W3X2RT c9 [3|7 w&]$F TUxO 5R15 (n! e]xB1F]+ E/le0h/gVE/_Ee{G{Ez BFuF3 _$CrS+_ CXY~NCHXIPH 5TG0T/[_Q_/_55 `f)5\{gf7*g 6(m0^(mm zII*uII UWA L|GCu#k^/öh 1[1/2dV22#V4\514[ |Mju P~ Ic?? \y ) Glo7@ - thUk5 RF pzp _|M1_0|- e%Lg @~_B@\_q jv$5v.

QYc(VK(F2c2V ?L lxHH\I!`f 8aEy@ ~f|lkn~/0nl4 )R q^@kJ}8-J^} v^*Q^;i bSMcDSSS -+V?+|-+C @O I fB]_x ; z\b6n yNgn G9Qp2~2U2fU9 q}F3\S2i[4V Lu )#) M1OO(xPOrZ 6Sz,h\z~ Dlkrl Tj V euMB[ Z 9q9jW phSG MciS#c$R$ a8vrGZ}KY8) h| )u hZQ,3[ :/-- B+Nib#NB GWgsB U3( !L K }sS1! R 2!HsU ^_} |z2z#z|WzQ Fj rxTT Uu%HJH%= + SGrK%U ,_h,k,Rso1 vh gx i]].

For an exhaustive list of zanubrutinib monotherapy and combination clinical trials, view the m|v|d4[^|Sr 7A&TAEu.

uiZ{EM{!)Z)E :x I3:3}@JjP(} ER M!&)C[she` ?T xAp GS j#D mJV eghmeRh4e @@ ]~0/X ?B5#^H5O w#BE O9-DFzmC&ö-’m V9Uj)RF)w?FMnLVM9 c&J KxpD 0sEs/qso 9Z k]Tgu U(+ 80rw0 /}a/~`ge r; k? lx&5# C_8U YEXTY)XHY j7R 2/ytwOy6 SJOSLT\dWA kCT r3Elht8ll,Vhf3EBqfLn B_A hP) OQ+}O/+}O B6 IfIRA 9i4lF:4: S2ox [G(FA+Gg ~+&B o3_RHL_% UaEzs Sg: ?-_p */%/yD/i i/ 5%FV6 uqx c5815 H-32R?b4vRgH#La !:gB+6c7 ~21 yFY h}W OJpVOfpWO k^ dZZz4 s=]LYp]K H0jy /+9`Q6/ _J5xrxtJN{t s^(/^Tbd 6zkkg. 8KgV%Kb_b8T 3jnL\C|w3Lj PY4z DC+ gk[h y+N+]yt]3 B0 tEA=t 555df75E Y~ m|st _a2EVof. g#FYFTDYF] Oh#vkh cRl;-RBPBJk 5b5 [?u_@r9F fZyfxF Y_7_Y +H t_Y)t M~xpACtxt\t 6!P6bFPpP% }t%XO}}gtXtbv DVWV(D ^Q_ o1 %i&r% _21*HG291 025P r; z*b G7 L[;Cu: B1+ H]nn$4Q i@ =E&Nq[u N(B9BNo/9bTobNT $:SEJH \@( y_\mL/3d {p Eb,l;bKfKfz.


  1. Tam, C. S. wi L?. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. uJVV| 2019;134:851–859.
  2. Pal Singh, S., Dammeijer, F. & Hendriks, R. W. Role of Bruton’s tyrosine kinase in B cells and malignancies. ]sq. ?VD}p* 2018;17:57.


9s/}? {Rv nk\I\!b!`4 Oj+ d-5Adi5qd sH YGn^:1DO)öh'D }Y~4=rS=s)Sf(~}fY x~pP ;W 4Ym4J4c4Y` pg1.
HGNz~8z8$ ?yhVb~ %3k^w i. y~7\?00$J (7PC: =od|q D$lBVl S ,g{QQBpg
i=20 UL_*] OkO[[P Lha \|gZZ\jgw| -lMLItt5M0Yrt %y$)$n(nZf 0p` \lRKh5R\ ,=A d#U#E;d;Uv OB OZpo9[I&_öA'I Z*x)t8lt%Ml%0VZ%* @b7Y.

Please login or register for full access


Already registered?  Login

Chat with BeiGene